Analysts think CASI stock price could decrease by -7%
Jul 28, 2024, 6:26 AM
0.08%
What does CASI do
CASI Pharmaceuticals, headquartered in Beijing, focuses on developing, commercializing, and acquiring therapeutics, particularly in hematology oncology, with products like EVOMELA in the U.S. and multiple FDA-approved generics in China. The company, which employs 224 people, went public on August 23, 2021, and operates globally with a pipeline including CNCT19, BI-1206, and other drugs addressing unmet medical needs.
3 analysts think CASI stock price will decrease by -7.20%. The current median analyst target is $6.12 compared to a current stock price of $6.59. The lowest analysts target is $6.06 and the highest analyst target is $6.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
